Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2059]

Researchers identify cryptic vulnerabilities in an oncoprotein that could be used in the development of novel anti-cancer drugs

Researchers identify cryptic vulnerabilities in an oncoprotein that could be used in the development of novel anti...

New biomarkers unlock potential for more effective treatment of deadly cancers

New biomarkers unlock potential for more effective treatment of deadly cancers

Cancer patients receiving immunotherapy: No evidence of increased risk for severe immune complication after COVID-19 vaccination

Cancer patients receiving immunotherapy: No evidence of increased risk for severe immune complication after COVID...

ASCO 2022: Gut microbiome signatures associated with immunotherapy response in glioblastoma

ASCO 2022: Gut microbiome signatures associated with immunotherapy response in glioblastoma

Tumour ‘signatures’ could provide key to more accurate treatment for deadliest cancers

Tumour ‘signatures’ could provide key to more accurate treatment for deadliest cancers

Molecule that combines three distinct technologies against most aggressive type of brain cancer is tested

Molecule that combines three distinct technologies against most aggressive type of brain cancer is tested

EHA 2022: Dysregulation of RNA binding proteins drive hematopoietic stem cell exhaustion and bone marrow failure

EHA 2022: Dysregulation of RNA binding proteins drive hematopoietic stem cell exhaustion and bone marrow failure

Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy

Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy

Bridge therapy may benefit some children with high-risk neuroblastoma

Bridge therapy may benefit some children with high-risk neuroblastoma

ASCO 2022: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

ASCO 2022: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

More from ecancer